ライフサイエンスコーパス: graft surgery

1 onary angioplasty and coronary artery bypass graft surgery).

2 ntion [PCI], PCI, and coronary artery bypass graft surgery).

3 about candidates for coronary artery bypass graft surgery.

4 hythm, and undergoing coronary artery bypass graft surgery.

5 long-term efficacy of coronary artery bypass graft surgery.

6 ntervention, and redo coronary artery bypass graft surgery.

7 g-term outcomes after coronary artery bypass graft surgery.

8 7 patients undergoing coronary artery bypass graft surgery.

9 ons related to trabeculectomy and/or corneal graft surgery.

10 onary angioplasty and coronary artery bypass graft surgery.

11 n patients undergoing coronary artery bypass graft surgery.

12 4 patients undergoing coronary artery bypass graft surgery.

13 el disease undergoing coronary artery bypass graft surgery.

14 -term mortality after coronary artery bypass graft surgery.

15 2 patients undergoing coronary artery bypass graft surgery.

16 SVG thrombosis after coronary artery bypass graft surgery.

17 8 patients undergoing coronary artery bypass graft surgery.

18 ndergoing nonemergent coronary artery bypass graft surgery.

19 ical therapy alone or coronary artery bypass graft surgery.

20 onary intervention or coronary artery bypass graft surgery.

21 ) patients undergoing coronary artery bypass graft surgery.

22 es undergoing primary coronary artery bypass graft surgery.

23 atients who underwent coronary artery bypass graft surgery.

24 es undergoing primary coronary artery bypass graft surgery.

25 n patients undergoing coronary artery bypass graft surgery.

26 infarction following coronary artery bypass graft surgery.

27 ng and after off-pump coronary artery bypass graft surgery.

28 t-term sedation after coronary artery bypass graft surgery.

29 bidity compared with on-pump coronary bypass graft surgery.

30 nt complication after coronary artery bypass graft surgery.

31 9 patients undergoing coronary artery bypass graft surgery.

32 previous multi-vessel coronary artery bypass graft surgery.

33 on complication after coronary artery bypass graft surgery.

34 use of bleeding after coronary artery bypass graft surgery.

35 he need for emergency coronary artery bypass graft surgery.

36 te transfusions after coronary artery bypass graft surgery.

37 .04) transfused after coronary artery bypass graft surgery.

38 g complications after coronary artery bypass graft surgery.

39 to have prior PCI or coronary artery bypass graft surgery.

40 routine partial thickness connective tissue graft surgery.

41 re, and for 5 days following, cardiac bypass graft surgery.

42 en, who had undergone coronary artery bypass graft surgery.

43 c shock, and low-risk coronary artery bypass graft surgery.

44 n undergoing isolated coronary artery bypass graft surgery.

45 sites were performing coronary artery bypass graft surgery.

46 or patient undergoing coronary artery bypass graft surgery.

47 bleeding unrelated to coronary artery bypass graft surgery.

48 ke when compared with coronary artery bypass graft surgery.

49 isk of mortality with coronary artery bypass graft surgery.

50 neous coronary intervention (PCI) and bypass graft surgery.

51 deemed ineligible for coronary artery bypass graft surgery.

52 re), and a history of coronary artery bypass graft surgery.

53 en, and 30% had prior coronary artery bypass graft surgery.

54 th angiography-guided coronary artery bypass graft surgery.

55 y and mortality after coronary artery bypass grafting surgery.

56 e likely to die after coronary artery bypass grafting surgery.

57 s and were undergoing coronary artery bypass grafting surgery.

58 s undergoing isolated coronary artery bypass grafting surgery.

59 (-0.717; -0.787) and coronary artery bypass graft surgery (-0.541; -0.618).

60 bleeding unrelated to coronary artery bypass graft surgery (1.6% vs 2.3%, RR 0.67, 95% CI 0.49-0.92;

61 or repeat procedures (coronary artery bypass graft surgery: 10.7% versus 6.8%, P=0.04, adjusted hazar

62 .4% vs. 83.7%), prior coronary artery bypass graft surgery (19.8% vs. 61.2%), peripheral vascular dis

63 2.72]; P < .001), and coronary artery bypass graft surgery (3.7% vs 1.3%; AOR, 3.00 [2.63 to 3.41]; P

64 us (45%) and previous coronary artery bypass graft surgery (34%).

65 angioplasty (55%) and coronary artery bypass graft surgery (38%).

66 0.0001) and both post-coronary artery bypass graft surgery (38%, P=0.048) and post-PCI (57%, P<0.0001

67 ial infarction (MI) (45.8%), coronary bypass graft surgery (39.2%), chronic renal failure (18.8%), an

68 curred, including 140 coronary artery bypass graft surgeries (4.1%) and 114 percutaneous coronary int

69 ery (11 patients) and coronary artery bypass graft surgery (4 patients).

70 4), and major bleeding not related to bypass graft surgery (6.9%vs 10.5%, -3.6% [-5.5 to -1.7], 0.64

71 ; colectomy [14 074]; coronary artery bypass graft surgery [6378]) by an in-network primary surgeon a

72 90-day mortality post-coronary artery bypass graft surgery 7% versus 3%, P=0.03; post-PCI 10% versus

73 7 patients undergoing coronary artery bypass graft surgery, 7.0% of whom received LAA closure.

74 arget lesion failure (coronary artery bypass graft surgery: 8.9% versus 3.9%, P<0.001, adjusted hazar

75 e (63% versus 21%) or coronary artery bypass graft surgery (81% versus 7%).

76 assignment, and years since coronary bypass graft surgery, a CES-D score > or =16 was positively ass

77 n patients undergoing coronary artery bypass graft surgery after 4 wk of consuming a low-GI diet than

78 whites after primary coronary artery bypass graft surgery after adjustment for other covariates (P<0

79 ved satisfaction with coronary artery bypass graft surgery after administration of DEX or propofol fo

80 ity of data comparing coronary artery bypass graft surgery against newer generation stents.

81 of whom 264 underwent coronary artery bypass graft surgery and 487 underwent percutaneous coronary in

82 Guideline Update for Coronary Artery Bypass Graft Surgery and actual clinical practice.

83 drug eluting stents, coronary-artery bypass graft surgery and anti-thrombosis.

84 sk of mortality after coronary artery bypass graft surgery and can be used for informed consent and a

85 n-hospital Q-wave MI, coronary artery bypass graft surgery and death were 0.4%, 1.9% and 1.4%, respec

86 rom vein leftovers of coronary artery bypass graft surgery and discarded atrial specimens of transpla

87 atients who underwent coronary artery bypass graft surgery and had an angiogram performed up to 18 mo

88 iaries undergoing any coronary artery bypass graft surgery and higher observed mortality rates (1.7%-

89 VGF is common after coronary artery bypass graft surgery and is associated with repeat revasculariz

90 inical outcomes after coronary artery bypass graft surgery and myocardial infarction in women.

91 multivessel disease, coronary artery bypass graft surgery and percutaneous coronary intervention are

92 ry revascularization (coronary artery bypass graft surgery and percutaneous transluminal coronary ang

93 pt closure, emergency coronary artery bypass graft surgery and restenosis, but do not prevent myocard

94 improvements are the outcome of the initial graft surgery and that the gingivoplasty procedure does

95 cardial infarction or coronary artery bypass graft surgery and those with severe heart failure sympto

96 ctomy, thyroidectomy, coronary artery bypass graft surgery, and carotid endarterectomy.

97 cular surgery, organ transplantation, tissue-graft surgery, and cases managed with low mean arterial

98 rtic aneurysm repair, coronary artery bypass graft surgery, and craniotomy, and for RS of 4 postopera

99 nary intervention and coronary artery bypass graft surgery, and differences in this outcome often dri

100 smoking, no previous coronary artery bypass graft surgery, and left anterior descending artery targe

101 ounger age, history of prior coronary bypass graft surgery, and non-white race.

102 yocardial infarction, coronary artery bypass graft surgery, and repeat PCI were primary outcomes comp

103 12 to 18 months after coronary artery bypass graft surgery, and subsequent clinical outcomes.

104 concentrations after coronary artery bypass graft surgery are nearly universally elevated, are deter

105 prediction models for coronary artery bypass grafting surgery are limited to in-hospital or 30-day en

106 onary intervention or coronary artery bypass graft surgery as appropriate) plus GDMT reduces rates of

107 s undergoing elective coronary artery bypass graft surgery at a single tertiary centre could benefit

108 s undergoing isolated coronary artery bypass grafting surgery at 33 medical centers in Michigan betwe

109 f patients undergoing coronary artery bypass grafting surgery at the remaining hospitals and for sele

110 P<0.001); history of coronary artery bypass graft surgery (beta=1.32; CI, 1.28-1.32; P<0.001); 2, 3,

111 re change in rates of coronary artery bypass graft surgery between 2002 to 2003 and 2008 to 2009 amon

112 e patients undergoing coronary artery bypass graft surgery between January 1, 2005, and December 31,

113 ing isolated off-pump coronary artery bypass graft surgery between January 2000 and June 2002.

114 nary intervention, or coronary artery bypass graft surgery between January 2000 and September 2007 fr

115 R + CABG) concomitant coronary artery bypass graft surgery between November 10, 1987 through June 30,

116 (VGF) is common after coronary artery bypass graft surgery, but its relationship with long-term clini

117 d be standard care in coronary artery bypass graft surgery, but vein quality and clinical outcomes ha

118 readmission following coronary artery bypass grafting surgery by using nationally representative clin

119 ) (2.3% vs. 3.0%) and coronary artery bypass graft surgery (CABG) (1.3% vs. 1.4%) were similar in wom

120 oplasty (PTCA) or for coronary artery bypass graft surgery (CABG) 40 vs. 46%, p = NS).

121 ) with survival after coronary artery bypass graft surgery (CABG) among diabetics in the Veterans Aff

122 atients with previous coronary artery bypass graft surgery (CABG) and acute myocardial infarction (AM

123 elines for the use of coronary artery bypass graft surgery (CABG) and percutaneous coronary intervent

124 rvival and subsequent coronary artery bypass graft surgery (CABG) and percutaneous coronary intervent

125 erum biomarkers after coronary artery bypass graft surgery (CABG) are associated with increased mediu

126 ntervention (PCI) and coronary artery bypass graft surgery (CABG) are being applied to high-risk popu

127 Coronary artery bypass graft surgery (CABG) compared with percutaneous coronary

128 rvival advantage with coronary artery bypass graft surgery (CABG) compared with percutaneous translum

129 ecific causes of post-coronary artery bypass graft surgery (CABG) deaths in the PLATO (Platelet Inhib

130 he need for emergency coronary artery bypass graft surgery (CABG) decreased significantly (p(trend) <

131 the first year after coronary artery bypass graft surgery (CABG) despite aspirin use.

132 h heart failure after coronary artery bypass graft surgery (CABG) has not been examined in a contempo

133 ional risk models for coronary artery bypass graft surgery (CABG) have gained widespread acceptance,

134 intervention (PCI) or coronary artery bypass graft surgery (CABG) in physician-directed and patient-c

135 brillation (AF) after coronary artery bypass graft surgery (CABG) is associated with increased morbid

136 Coronary artery bypass graft surgery (CABG) is widely used for the treatment of

137 Patients having coronary artery bypass graft surgery (CABG) may be subject to different care pr

138 lihood of in-hospital coronary artery bypass graft surgery (CABG) might be useful in selecting patien

139 t public reporting of coronary artery bypass graft surgery (CABG) mortality might result in case sele

140 who underwent repeat coronary artery bypass graft surgery (CABG) or percutaneous coronary interventi

141 ta-blocker therapy on coronary artery bypass graft surgery (CABG) outcomes has not been assessed.

142 rative clopidogrel on coronary artery bypass graft surgery (CABG) outcomes.

143 Guidelines recommend coronary artery bypass graft surgery (CABG) over percutaneous coronary interven

144 A major advantage of coronary artery bypass graft surgery (CABG) relative to percutaneous coronary i

145 atients; 312 had only coronary artery bypass graft surgery (CABG) surgery, 37 had both valve and CABG

146 is a complication of coronary artery bypass graft surgery (CABG) that can be difficult to diagnose.

147 onary artery disease, coronary artery bypass graft surgery (CABG) was associated with a lower rate of

148 Diabetes) trial found coronary artery bypass graft surgery (CABG) was associated with better clinical

149 ith CAD indicated for coronary artery bypass graft surgery (CABG) were included.

150 guidelines recommend coronary artery bypass graft surgery (CABG) when treating significant de novo l

151 ized trials comparing coronary artery bypass graft surgery (CABG) with percutaneous coronary interven

152 ized trials comparing coronary artery bypass graft surgery (CABG) with percutaneous transluminal coro

153 troke occurring after coronary artery bypass graft surgery (CABG) without cardiopulmonary bypass (off

154 s complications after coronary artery bypass graft surgery (CABG), and their etiology and implication

155 angioplasty (PTCA) or coronary artery bypass graft surgery (CABG), should these interventions be need

156 patients treated with coronary artery bypass graft surgery (CABG), we evaluated the impact of providi

157 Non-coronary artery bypass graft surgery (CABG)-related major bleeding within 30 da

158 n patients undergoing coronary artery bypass graft surgery (CABG).

159 intervention (PCI) or coronary artery bypass graft surgery (CABG).

160 n patients with prior coronary artery bypass graft surgery (CABG).

161 a worse outcome after coronary artery bypass graft surgery (CABG).

162 moses during off-pump coronary artery bypass graft surgery (CABG).

163 (AVR) at the time of coronary artery bypass graft surgery (CABG).

164 oplasty compared with coronary artery bypass graft surgery (CABG).

165 ngioplasty (PTCA) and coronary artery bypass graft surgery (CABG).

166 angioplasty (PTCA) or coronary artery bypass graft surgery (CABG).

167 nels as an adjunct to coronary artery bypass graft surgery (CABG).

168 early and late after coronary artery bypass graft surgery (CABG).

169 surgery (MIDCAB) and coronary artery bypass graft surgery (CABG).

170 oplasty (PTCA) versus coronary artery bypass graft surgery (CABG).

171 erm outcome following coronary artery bypass graft surgery (CABG).

172 r operative risk with coronary artery bypass graft surgery (CABG).

173 ve patients underwent coronary artery bypass graft surgery (CABG); all received RA and left internal

174 Patients underwent coronary artery bypass graft surgery (CABG, n=203), percutaneous coronary inter

175 raphic findings after coronary artery bypass grafting surgery (CABG) are lacking.

176 rvention (PCI) versus coronary artery bypass grafting surgery (CABG) on mortality at 5 years differed

177 ntion (PCI) and after coronary artery bypass grafting surgery (CABG).

178 rdiopulmonary bypass (coronary artery bypass graft surgery [CABG]) in a broad cross section of U.S. h

179 al revascularization (coronary artery bypass graft surgery [CABG]) versus TAXUS Express (Boston Scien

180 intervention [PCI] vs coronary artery bypass graft surgery [CABG]) were prospectively selected on the

181 revascularization, or coronary artery bypass graft surgery--can be selected.

182 patients intended for coronary artery bypass graft surgery compared with the subgroup intended for pe

183 xcluding various post-coronary artery bypass graft surgery complications.

184 na (1.91; 1.59-2.29), coronary artery bypass graft surgery/coronary angioplasty procedure/stent (1.35

185 ly, and 25% underwent coronary artery bypass graft surgery (CTO bypassed in 88%).

186 younger age, previous coronary artery bypass graft surgery, depressive symptoms, and financial diffic

187 Notably, the need for bypass graft surgery due to restenosis is reduced after TAXUS s

188 Coronary artery bypass graft surgery during the index hospitalization, higher m

189 off-pump and on-pump coronary artery bypass graft surgery for follow-up longer than 5 years is not w

190 t of P4P on access to coronary artery bypass graft surgery for high-risk patients with AMI.

191 had isolated primary coronary artery bypass graft surgery for multivessel coronary artery disease fr

192 e undergoing isolated coronary artery bypass graft surgery from 2004 to 2006.

193 al augmentation procedure (connective tissue graft; surgery group) and an equal number of contralater

194 c shock (n=1705), and coronary artery bypass graft surgery groups.

195 inhibitors (ACEIs) in coronary artery bypass graft surgery has been erratic and controversial.

196 ilure associated with coronary artery bypass graft surgery has significantly increased from 1988 to 2

197 e patients treated by coronary artery bypass graft surgery having at least 1 angiographically interme

198 is recommended after coronary artery bypass graft surgery; however, the consequences of longer wait

199 proves survival after coronary artery bypass graft surgery; however, the survival benefit of multiple

200 ecrosis and Damage in Coronary Artery Bypass Graft Surgery II Trial, a phase 3, multicenter, randomiz

201 t performed 1 or more coronary artery bypass graft surgeries in a given calendar year were classified

202 s undergoing isolated coronary artery bypass graft surgery in 2003.

203 ys and 6 months after coronary artery bypass graft surgery in 229 subjects receiving aspirin monother

204 ardial infarctions or coronary artery bypass graft surgery in 267,427 fee-for-service beneficiaries a

205 first 24 hours after coronary artery bypass graft surgery in 847 consecutive patients.

206 ho underwent isolated coronary artery bypass graft surgery in July through December 2000.

207 usion during isolated coronary artery bypass graft surgery in patients with atrial fibrillation is as

208 syndromes or previous coronary artery bypass graft surgery in periods before (2010 through 2011) and

209 autograft was superior to amniotic membrane graft surgery in reducing the rate of pterygium recurren

210 Screening led to bypass graft surgery in seven patients.

211 lassified as isolated coronary artery bypass grafting surgery in the administrative cohort.

212 atients who underwent coronary artery bypass graft surgery, in whom both prerequisites could be readi

213 nary intervention and coronary artery bypass graft surgery independently contributed to the significa

214 n Patients Undergoing Coronary Artery Bypass Grafting Surgery) investigated whether ticagrelor added

215 An acute renal event after coronary bypass graft surgery is associated with high mortality and subs

216 ACEI treatment after coronary artery bypass graft surgery is associated with nonfatal in-hospital is

217 ilure associated with coronary artery bypass graft surgery is increasing in the United States.

218 on-pump and off-pump coronary artery bypass graft surgery is not statistically significant.

219 r patients undergoing coronary artery bypass graft surgery is unknown.

220 For coronary artery bypass graft surgery, mortality rates in 1998 to 1999 differed

221 abase associated with coronary artery bypass graft surgery, myocardial infarction/cardiogenic shock,

222 underwent in-hospital coronary artery bypass graft surgery (N = 2,258,711 visits).

223 interval, 0.55-0.67), coronary artery bypass graft surgery (n=1077; hazard ratio, 0.68; 95% confidenc

224 ass index, history of coronary artery bypass graft surgery, number of treated lesions, and chronic to

225 Off-pump coronary artery bypass graft surgery (OPCAB) has been performed for many years,

226 justment for hospital coronary artery bypass graft surgery or cardiac catheterization capability.

227 larization procedure: coronary artery bypass graft surgery or percutaneous coronary intervention (PCI

228 to-expected ratio for coronary artery bypass graft surgery or percutaneous coronary intervention was

229 nd underwent isolated coronary artery bypass graft surgery or percutaneous coronary intervention with

230 evascularization with coronary artery bypass graft surgery or percutaneous coronary intervention).

231 on by procedure type (coronary artery bypass graft surgery or percutaneous coronary intervention).

232 of revascularization, coronary artery bypass graft surgery or percutaneous coronary intervention.

233 ortality after either coronary artery bypass graft surgery or percutaneous coronary interventions sep

234 are not suitable for coronary artery bypass graft surgery or percutaneous transluminal coronary angi

235 atients with previous coronary artery bypass graft surgery or presenting with acute ST-segment elevat

236 ood of ACEI/ARB after coronary artery bypass grafting surgery or in patients with renal insufficiency

237 and those undergoing coronary artery bypass graft surgery (OR 0.58; 95% CI 0.55 to 0.60).

238 ivors after surgical (coronary artery bypass graft surgery) or percutaneous (percutaneous coronary in

239 n, emergent or urgent coronary artery bypass graft surgery, or cerebrovascular accident after PCI.

240 rtic aneurysm repair, coronary artery bypass graft surgery, or craniotomy.

241 e death, MI, emergent coronary artery bypass graft surgery, or target lesion revascularization) and A

242 vage fluid rose after coronary artery bypass graft surgery (p < 0.05), but there was no significant c

243 r mortality (58% post-coronary artery bypass graft surgery, P=0.002; 67% post-PCI, P<0.0001).

244 of 47 984 consecutive coronary artery bypass grafting surgeries performed from 1992 to 2014 among 7 m

245 of Thoracic Surgeons coronary artery bypass graft surgery population studied, the median age was 66

246 clinically (previous coronary artery bypass graft surgery prevalence, 48% versus 24%; P<0.001) and a

247 vessel disease, prior coronary artery bypass graft surgery, prior MI, and smoking.

248 patients selected for coronary artery bypass graft surgery, prompt coronary revascularization was ass

249 djusted mortality for coronary artery bypass graft surgery, public reporting on outcomes has expanded

250 angiography rates and coronary artery bypass graft surgery rates (R(2)=0.41) with the suggestion of a

251 Coronary artery bypass graft surgery rates for high-risk patients in Premier de

252 Coronary artery bypass graft surgery rates for patients with AMI in Premier dec

253 A coronary artery bypass grafting surgery readmission measure suitable for public

254 clinical outcomes in coronary artery bypass graft surgery remains unclear.

255 onary intervention or coronary artery bypass graft surgery, respectively.

256 al year 2003 isolated coronary artery bypass grafting surgery results based on an audited and validat

257 ization among the 381 coronary artery bypass graft surgery-selected patients in the highest angiograp

258 a strategy of prompt coronary artery bypass graft surgery significantly reduces the rate of death/my

259 rwent either isolated coronary artery bypass graft surgery, single noncoronary artery bypass graft su

260 rmed angina pectoris, coronary artery bypass graft surgery, stents, and angioplasty.

261 isk groups within the coronary artery bypass graft surgery stratum, or in any subgroups within the pe

262 coronary angioplasty, coronary artery bypass graft surgery, stroke).

263 l infarction, angina, coronary artery bypass graft surgery, stroke, claudication, gangrene, or tissue

264 s vein grafts used in coronary artery bypass graft surgery suffer from lower patency rates compared t

265 Use is higher after coronary artery bypass graft surgery than with acute myocardial infarctions not

266 major complication of coronary artery bypass graft surgery that is strongly associated with in-hospit

267 ary syndrome/no prior coronary artery bypass graft surgery that were rated as inappropriate decreased

268 For coronary artery bypass graft surgery, the relationship is modest, and there app

269 of TMR combined with coronary artery bypass graft surgery (TMR + CABG) versus bypass alone in patien

270 d patients with a history of coronary bypass graft surgery to either an aggressive or a moderate lipi

271 ft surgery, single noncoronary artery bypass graft surgery, two procedures, or three or more procedur

272 s undergoing off-pump coronary artery bypass graft surgery using a large patient sample and a risk-ad

273 nonemergent, isolated coronary artery bypass grafting surgery using cardiopulmonary bypass by 32 surg

274 disparity in isolated coronary artery bypass grafting surgery volume (4440 clinical, 5657 administrat

275 unction who underwent coronary artery bypass graft surgery was 19.8%.

276 Performance of coronary artery bypass graft surgery was also associated with a lower recurrent

277 FFR-guided coronary artery bypass graft surgery was associated with a lower number of graf

278 infarction following coronary artery bypass graft surgery was associated with a significant increase

279 reported that EVH for coronary artery bypass graft surgery was associated with worse outcomes than wi

280 In 429 patients, coronary artery bypass graft surgery was based solely on angiography (angiograp

281 ion >50%]) undergoing coronary artery bypass graft surgery was obtained by subepicardial needle biops

282 Coronary artery bypass graft surgery was the only significant predictor of late

283 g not associated with coronary artery bypass graft surgery were also increased among patients with IP

284 Admissions after coronary artery bypass graft surgery were excluded.

285 MIs related to coronary artery bypass graft surgery were few, but numerical excess was observe

286 ted intraocular pressure (IOP) after corneal graft surgery were included.

287 s undergoing elective coronary artery bypass graft surgery were randomized to atorvastatin 40 mg/d or

288 on and indication for coronary artery bypass graft surgery were randomized to botulinum toxin (Xeomin

289 y patients undergoing coronary artery bypass graft surgery were randomized to RIPC (n=30) or control

290 s undergoing elective coronary artery bypass graft surgery were randomly assigned to either a remote

291 nterventions, such as coronary artery bypass graft surgery, were also included, totaling 362 patients

292 that patients having coronary artery bypass graft surgeries with an internal mammary artery (IMA) ha

293 ents before and after coronary artery bypass graft surgery with cardiopulmonary bypass and lobectomy.

294 tudy of 4801 patients having coronary bypass graft surgery with cardiopulmonary bypass from November

295 oing primary elective coronary artery bypass graft surgery with cardiopulmonary bypass to determine w

296 n patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass, increased atr

297 al stunning following coronary artery bypass graft surgery with cardiopulmonary bypass, it reduced ca

298 derwent jugular-carotid interposition bypass graft surgery with intraoperative adenoviral gene transf

299 s undergoing isolated coronary artery bypass graft surgery with LIMA to left anterior descending arte

300 tudy population, 1482 coronary artery bypass grafting surgeries with BIMA were identified, and 1297 p